Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease

Background & Aims: To date, no pharmacological therapy has been approved for non-alcoholic fatty liver disease (NAFLD). The aim of the present study was to evaluate the therapeutic potential of poly ADP-ribose polymerase (PARP) inhibitors in mouse models of NAFLD. Methods: As poly ADP-ribosylation (PARylation) of proteins by PARPs consumes nicotinamide adenine dinucleotide (NAD+), we hypothesized that overactivation of PARPs drives NAD+ depletion in NAFLD. Therefore, we assessed the effectiveness of PARP inhibition to replenish NAD+ and activate NAD(+)-dependent sirtuins, hence improving hepatic fatty acid oxidation. To do this, we examined the preventive and therapeutic benefits of the PARP inhibitor (PARPi), olaparib, in different models of NAFLD. Results: The induction of NAFLD in C57BL/6J mice using a high fat high-sucrose (HFHS)-diet increased PARylation of proteins by PARPs. As such, increased PARylation was associated with reduced NAD+ levels and mitochondrial function and content, which was concurrent with elevated hepatic lipid content. HFHS diet supplemented with PARPi reversed NAFLD through repletion of NAD+, increasing mitochondrial biogenesis and beta-oxidation in liver. Furthermore, PARPi reduced reactive oxygen species, endoplasmic reticulum stress and fibrosis. The benefits of PARPi treatment were confirmed in mice fed with a methionine- and choline-deficient diet and in mice with lipopolysaccharide-induced hepatitis; PARP activation was attenuated and the development of hepatic injury was delayed in both models. Using Sirt1(heP-/-) mice, the beneficial effects of a PARPi-supplemented HFHS diet were found to be Sirt1-dependent. Conclusions: Our study provides a novel and practical pharmacological approach for treating NAFLD, fueling optimism for potential clinical studies. Lay summary: Non-alcoholic fatty liver disease (NAFLD) is now considered to be the most common liver disease in the Western world and has no approved pharmacological therapy. PARP inhibitors given as a treatment in two different mouse models of NAFLD confer a protection against its development. PARP inhibitors may therefore represent a novel and practical pharmacological approach for treating NAFLD. (C) 2016 European Association for the Study of the Liver. Published by Elsevier B.V.

Published in:
Journal Of Hepatology, 66, 1, 132-141
Amsterdam, Elsevier Science Bv

 Record created 2017-01-24, last modified 2018-12-03

Rate this document:

Rate this document:
(Not yet reviewed)